Necrólisis epidérmica tóxica con desenlace fatal causada por el uso concomitante de carbamazepina, cilostazol y omeprazol: A propósito de un caso

Martín, I. Concepción; Espinosa, MA Fernandez de Palencia; Corro, B. Garrido; Coira, Amparo

doi:10.1016/j.farma.2010.09.008

Cited by 3 publications

(1 citation statement)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since cilostazol and carbamazepine are not structurally related, multiple drug hypersensitivity is a more likely explanation than cross-reactivity [ 32 ]. A 78-year-old female patient developed fatal toxic epidermal necrolysis (TEN) also under co-medication with carbamazepine, cilostazol and omeprazole [ 33 ]. Two further cases in the US of TEN under cilostazol have been reported to the World Health Organization (WHO)/VigiSearch.…”

Section: Antiplatelet Drugsmentioning

confidence: 99%

Hypersensitivity reactions to modern antiplatelet and anticoagulant drugs

Scherer

2015

Allergo J Int

View full text Add to dashboard Cite

Anticoagulation and antiplatelet drugs are among the most commonly used medical drugs. In addition to the long-established heparins, hirudins, coumarins and antiplatelet drugs such as acetylsalicylic acid, numerous novel and predominantly synthetic pharmacologic agents have come onto the market in recent years. These new agents act at various sites in coagulation and have significantly broadened treatment options. Whilst immunological hypersensitivity reactions are on the whole rare, they have a considerable impact on patient management when they do occur. The present overview discusses the currently known hypersensitivity reactions to anticoagulant and antiplatelet agents, with particular attention to the newer substance classes including P2Y12 inhibitors, glycoprotein IIb/IIIb receptor antagonists, direct factor Xa inhibitors and direct thrombin inhibitors.

show abstract

Section: Antiplatelet Drugsmentioning

confidence: 99%